Everything you need to know about TMS Around the World: How Europe and the US Approach Brain Stimulation Differently — how it works, what it costs, and how to find a provider who actually knows what they're doing.

Transcranial magnetic stimulation is one of the most internationally collaborative areas of clinical neuroscience, with research spanning continents and regulatory frameworks converging around shared scientific evidence. Yet significant differences exist in how TMS is practiced in Europe versus the United States. Understanding these differences illuminates broader themes in healthcare regulation, insurance coverage, and the translation of research into clinical practice.

Regulatory Frameworks

United States: FDA Clearance

In the United States, TMS devices are regulated as medical devices by the Food and Drug Administration (FDA). The FDA has cleared TMS for:

• Major Depressive Disorder (2008, updated 2018) — patients who have not responded to at least one antidepressant
• Obsessive-Compulsive Disorder — adjunct to medication
• Smoking cessation
• Anxious depression

The FDA clearance pathway requires demonstration of safety and efficacy through clinical trials. Off-label uses (conditions not specifically cleared) are permitted but are not covered by insurance.

Europe: CE Mark

In the European Union, TMS devices require CE marking under the Medical Device Regulation (MDR). The CE mark indicates compliance with EU safety and performance requirements. Unlike the FDA’s indication-specific clearance system, CE marking is device-level, allowing more flexibility in how devices are used clinically.

This difference has significant practical implications:

• Broader clinical use in Europe — once a device has CE marking, physicians can prescribe it for any condition they deem appropriate based on their clinical judgment
• More off-label prescribing — European clinicians may offer TMS for conditions that lack strong evidence, contributing to both innovation and potential overuse
• Less standardized practice — without specific cleared indications, treatment protocols may vary more widely

Insurance Coverage

United States: Variable and Restrictive

Insurance coverage for TMS in the US is inconsistent and often restrictive:

Medicare coverage varies by region based on Local Coverage Determinations (LCDs). Generally, Medicare covers TMS for:

• Treatment-resistant depression (typically 4+ medication failures)
• Patients who cannot tolerate medications
• Treatment in an outpatient setting

Medicaid coverage varies significantly by state, with some states offering no coverage.

Private insurers have highly variable policies:

• Most require prior authorization
• Many impose strict medication-failure criteria
• Coverage may be limited to specific devices
• Out-of-network access is often restricted

The average patient cost with insurance is $75-150 per session with 30-36 sessions typical.

Europe: More Comprehensive but Variable

European coverage patterns vary by country and healthcare system:

Nationalized systems (UK NHS, German GKV):

• TMS is increasingly covered for depression in many regions
• Coverage often requires specialist referral
• Limited to evidence-based protocols
• Patient costs are minimal or nonexistent

Social insurance systems (Germany, France, Netherlands):

• Strong coverage for established treatments
• More generous reimbursement for providers
• Supports wider availability of TMS clinics

Private systems:

• Coverage typically mirrors US patterns
• More flexibility in protocol selection

The variation in European coverage reflects different healthcare system structures, economic constraints, and national policies toward neuromodulation.

Clinical Practice Differences

Treatment Protocols

Both regions use similar core protocols, but emphasis differs:

United States:

• Standardization around FDA-cleared protocols
• Greater use of theta burst (iTBS) following FDA clearance
• Strong emphasis on treatment resistance criteria
• Typical course: 36 sessions over 6-9 weeks

Europe:

• More variation in protocols based on individual clinician preference
• Earlier adoption of novel approaches (accelerated protocols, personalized targeting)
• Shorter treatment courses in some centers
• Greater use of maintenance and booster protocols

Provider Landscape

United States:

• TMS typically administered by technicians under physician supervision
• Physician oversight may be remote (telemedicine supervision)
• Large TMS clinic chains (Greenbrook TMS, Neuro Wellness) have expanded access
• Many academic medical centers offer TMS

Europe:

• TMS often administered by physicians directly
• More academic medical center-based treatment
• Smaller clinic networks
• Greater involvement of clinical neurophysiologists

Access and Availability

United States:

• Approximately 2,500 TMS clinics nationwide
• Concentration in urban areas
• Rural access remains limited
• Wait times may be weeks to months

Europe:

• Wide variation by country — Germany and UK have the most TMS capacity
• Eastern European countries have less TMS availability
• Rural access is also challenging in many areas
• Some cross-border treatment (patients traveling to Germany from neighboring countries)

Research Priorities

United States Focus Areas

American TMS research emphasizes:

Clinical effectiveness — Large pragmatic trials comparing TMS to standard treatments in real-world settings

Novel indications — PTSD, bipolar depression, addiction, chronic pain

Protocol optimization — Accelerated protocols, personalized targeting, maintenance strategies

Implementation science — How to expand access and integrate TMS into healthcare systems

Industry-sponsored research — Major TMS device companies fund clinical trials for new indications

European Focus Areas

European research tends to emphasize:

Basic neuroscience — Understanding mechanisms of TMS at the synaptic and network level

Personalized medicine — Using neuroimaging to guide treatment selection and targeting

Novel coil development — Engineering advances in targeting and depth penetration

Regulatory science — Contributing to EU regulatory frameworks for brain stimulation

International collaboration — European multi-center trials leverage diverse healthcare systems

Key Differences Summarized

Cross-Atlantic Learning

Both regions have lessons to offer:

From Europe:

• The value of broader clinical flexibility in driving innovation
• More comprehensive insurance coverage as a model for expansion
• Physician-administered treatment may allow better protocol individualization

From the United States:

• The benefits of defined FDA clearance for establishing treatment credibility
• Large-scale clinical effectiveness research
• The TMS clinic chain model for expanding access

The Future

Global TMS practice is converging:

• International guidelines from the International Federation of Clinical Neurophysiology (IFCN) provide shared recommendations
• European regulatory changes may create more specific indication requirements
• US coverage may expand as more insurers adopt Medicare-based criteria
• Global clinical trials will continue to generate evidence supporting broader use
• Telehealth may help equalize access across both regions

For patients considering TMS, understanding the international landscape can inform expectations and help identify optimal treatment options, including potential treatment abroad if domestic access is limited.